Dopamine-dependent nature of depression-like behavior in WAG/Rij rats with genetic absence epilepsy.
WAG/Rij rats given placebo showed a depression-like state as compared with normal Wistar rats (lacking convulsive pathology); this was analogous to the state previously seen in rats of this line, with decreased investigative activity in the open field test, increased immobility in the forced swimming test, and decreased consumption and preference for sucrose solution (anhedonia). Chronic administration of the tricyclic antidepressant imipramine (15 mg/kg, i.p., 15 days) had therapeutic (antidepressant) effects on depression-like behavior in WAG/Rij rats. After withdrawal of antidepressant therapy, the behavior of WAG/Rij rats was not significantly different from that of Wistar rats. Acute (single-dose) administration of the selective dopamine D2/D3 receptor antagonist raclopride (100 microg/kg, i.p., 15 min before the start of behavioral testing) increased the symptoms of depression-like behavior and suppressed the antidepressant effect of chronic administration of imipramine in WAG/Rij rats. Raclopride had no significant effect on behavior in Wistar rats. Administration of the dopamine D2/D3 receptor agonist parlodel (a therapeutic form of bromocriptine) cured the depression-like behavior of WAG/Rij rats and had no significant effect on behavior in Wistar rats, with the exception of a reduction in the duration of immobility in the forced swimming test. Imipramine and raclopride had no significant effect on the levels of total movement activity and anxiety in either WAG/Rij or Wistar rats. These results demonstrate the dopamine-dependent nature of depression-like behavior in WAG/Rij rats and show the possible involvement of dopamine D2 receptors in mediating the antidepressant effect of imipramine on genetically determined depression-like behavior in WAG/Rij rats.
Sarkisova
K Yu
KY
Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow. karine@online.ru
Kulikov
M A
MA
Midzyanovskaya
I S
IS
Folomkina
A A
AA
D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology; D001971:Bromocriptine / Q000494:pharmacology; D003863:Depression / Q000209:etiology / Q000235:genetics* / Q000523:psychology*; D004298:Dopamine / Q000502:physiology*; D018491:Dopamine Agonists / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000494:pharmacology; D004435:Eating / Q000187:drug effects; D004832:Epilepsy, Absence / Q000150:complications / Q000235:genetics* / Q000523:psychology*; D005518:Food Preferences / Q000187:drug effects; D007099:Imipramine / Q000494:pharmacology; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D020891:Raclopride / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D017208:Rats, Wistar; D013550:Swimming / Q000523:psychology
D000929:Antidepressive Agents, Tricyclic; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D001971:Bromocriptine; D020891:Raclopride; D007099:Imipramine; D004298:Dopamine